Last updated: February 13, 2026
Overview of NDC 65862-0036
NDC 65862-0036 corresponds to Apremilast (Otezla), a medication approved by the FDA for the treatment of psoriasis and psoriatic arthritis. Released by Amgen, this drug is available as an oral tablet with strengths of 30 mg and 10 mg.
Market Landscape
1. Indications and Approved Uses
- Moderate to severe plaque psoriasis
- Active psoriatic arthritis
2. Market Size and Demand
- Estimated global psoriasis market size was valued at approximately USD 2.8 billion in 2022, with a compound annual growth rate (CAGR) of 8%[1].
- The U.S. psoriasis market accounted for over 50% of global sales, driven by high prevalence and reimbursement coverage.
- Psoriatic arthritis drugs constitute a subset, with an estimated 1-2 million U.S. patients.
3. Competitive Environment
- Key competitors include biologics (e.g., Humira, Cosentyx, Stelara) and other oral agents such as methotrexate.
- Apremilast differentiates as an oral agent with a favorable safety profile compared to biologics, which require injections and are associated with higher immunosuppression risks.
- Its market share is approximately 4-6% within the psoriasis segment, reflecting moderate utilization but room for growth.
4. Regulatory and Reimbursement Factors
- Approved in multiple major markets: U.S., EU, Japan.
- Reimbursement coverage is generally broad in the U.S., supported by insurance plans due to its oral administration and safety profile.
- Price concessions and formulary placements influence actual sales volumes.
Price Projections
1. Current Pricing
- Average wholesale price (AWP): USD 1,200 – 1,300 per month for a typical 30-day supply[2].
- Actual negotiated net price likely 20-30% lower, depending on payers and discounts.
2. Short-term Outlook (Next 1-2 Years)
- Slight cost increase reflecting inflation and supply chain factors.
- Due to competitive pressure from biosimilars and generics in other indications, prices could decline by up to 5%, assuming increased competition does not offset.
| Year |
Estimated Monthly Price |
Notes |
| 2023 |
USD 1,250 |
Current average wholesale price |
| 2024 |
USD 1,200 – 1,225 |
Slight decrease due to market pressures |
| 2025 |
USD 1,150 – 1,200 |
Continued competitive adjustments |
3. Long-term Price Trends (Next 3-5 Years)
- Price stabilization is unlikely as biosimilar and generic options expand.
- US market may see a 10-15% cumulative price decline over five years.
- In international markets, pricing will vary significantly based on local policies, with some countries implementing price caps.
Revenue Forecasts
Based on current utilization:
- Estimated US annual sales for Otezla in psoriasis and psoriatic arthritis approximate USD 1.2 billion.
- Projected compound annual growth rate (CAGR) of 2-4% driven by new patient initiation and expanded indications.
Risks to Price Stability
- Increased biosimilar competition in key markets.
- Patent challenges or generic entry timelines.
- Pricing reforms aimed at drug cost containment.
Key Data Sources
- MarketWatch, 2022[1]
- IQVIA sales data, 2022[2]
- FDA and EMA approval databases
- Industry analyst reports
Key Takeaways
- The psoriasis and psoriatic arthritis market is competitive with slow but steady growth.
- NDC 65862-0036, marketed as Otezla, holds a moderate market share with pricing approximately USD 1,200/month in the U.S.
- Prices are expected to decline modestly over the next five years due to generic and biosimilar pressures.
- Long-term revenue potential remains stable but depends on market competition, regulatory changes, and payer policies.
FAQs
Q1: How does Apremilast compare to biologic therapies in efficacy?
A1:** It is generally less efficacious than biologics but offers a favorable safety profile and oral administration, which appeals to certain patient segments.
Q2: What factors could accelerate price declines?
A2: Entry of biosimilars, policy reforms targeting drug pricing, and increased market saturation.
Q3: Are there existing patents that protect Apremilast from generics?
A3:** Yes, patents protect Apremilast until approximately 2025-2027; patent expiration could lead to generic competition.
Q4: How does international market pricing differ?
A4:** Countries with price regulation or cost controls, like the UK or Canada, have significantly lower prices compared to the U.S.
Q5: What is the potential for expanding approved indications?
A5: Slight potential exists via ongoing clinical trials, but at present, the primary indications are psoriasis and psoriatic arthritis.
References
[1] MarketWatch. "Psoriasis Treatment Market Size, Share & Trends Analysis." 2022.
[2] IQVIA. "Pharmaceutical Pricing and Sales Data," 2022.
